News|Articles|November 5, 2025
Scaling Up Viral Vector Harvest with Ease and Regulatory Compliance
Key Takeaways
- Gene therapy's expansion with AAV and LV vectors demands scalable, efficient bioproduction solutions, particularly in cell lysis processes.
- The EU REACH restriction on Triton™ X-100 necessitates alternative solutions for compliant and efficient cell lysis.
The rapid rise of gene therapy using AAV and LV vectors has created urgent demand for scalable, high-performance bioproduction. A major challenge is cell lysis—where simplicity, compliance, and efficiency must align. With Triton™ X-100 under EU REACH restriction, a next-gen solution is needed. This paper explores how J.T.Baker® Cell Lysis Solution delivers ease of use, regulatory compliance, and process performance with low viscosity, a concentrated format, and endonuclease compatibility.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5